Wedbush lowered the firm’s price target on Edgewise Therapeutics to $23 from $27 and keeps an Outperform rating on the shares following the Q3 update. All efforts remain on track including the anticipated Phase 2 EDG-5506 LYNX data in DMD patients, the analyst tells investors in a research note, adding that the firm continues to see Edgewise’s EDG-5506 as a complementary agent and well positioned.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EWTX:
- JPMorgan healthcare/biotech analysts hold analyst/industry conference call
- Edgewise Therapeutics reports Q3 EPS (41c), consensus (40c)
- Edgewise Therapeutics announces expansion of EDG-5506 program in Duchenne
- Edgewise Therapeutics initiates enrollment of GRAND CANYON study
- Edgewise Therapeutics announces intial dosing in EDG-7500 trial